Patents Assigned to Immunocore Limited
-
Patent number: 11929151Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: January 26, 2021Date of Patent: March 12, 2024Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 11827688Abstract: The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA (SEQ ID NO:1)-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.Type: GrantFiled: June 2, 2017Date of Patent: November 28, 2023Assignee: Immunocore LimitedInventor: Christina Coughlin
-
Patent number: 11739441Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain comprising an alpha chain variable domain and a beta chain comprising a beta chain variable domain and the library comprises more than one TRAV gene product and/or more than one TRBV gene product, wherein the beta chain variable domain does not comprise one or more of a TRBV5-1, 5-3, 5-4, 5-5, 5-6, 5-7 or 5-8 gene product and wherein the plurality of TCRs do not consist essentially of TCRs comprising a TRAV12-2 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire and TCRs comprising a TRAV21 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire.Type: GrantFiled: August 18, 2021Date of Patent: August 29, 2023Assignee: Immunocore LimitedInventors: Peter Eamon Molloy, Arsen Valeryevich Volkov, Dhaval Jaykant Sangani, Graham Anthony Hood, Chandramouli Reddy Chillakuri
-
Patent number: 11739442Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.Type: GrantFiled: August 19, 2021Date of Patent: August 29, 2023Assignees: Immunocore Limited, Adaptimune LimitedInventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
-
Patent number: 11718657Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: June 19, 2018Date of Patent: August 8, 2023Assignee: Immunocore LimitedInventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
-
Patent number: 11639374Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: December 22, 2016Date of Patent: May 2, 2023Assignee: IMMUNOCORE LIMITEDInventors: Fiona Chester, Andrew Alexander Knox, Jonathan Patrick Lowther, Viren Vinubhai Patel, Emma Elizabeth Baston, Ruth Martinez Hague
-
Patent number: 11505590Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: April 7, 2017Date of Patent: November 22, 2022Assignee: IMMUNOCORE LIMITEDInventors: Conor Hayes, Linda Hibbert, Nathaniel Ross Liddy, Tara Mahon, Marine Raman
-
Patent number: 11440944Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.Type: GrantFiled: March 22, 2017Date of Patent: September 13, 2022Assignee: Immunocore LimitedInventors: Tara Mahon, Yi Li
-
Patent number: 11427624Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.Type: GrantFiled: December 15, 2021Date of Patent: August 30, 2022Assignee: Immunocore LimitedInventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
-
Patent number: 11136575Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain comprising an alpha chain variable domain and a beta chain comprising a beta chain variable domain and the library comprises more than one TRAV gene product and/or more than one TRBV gene product, wherein the beta chain variable domain does not comprise one or more of a TRBV5-1, 5-3, 5-4, 5-5, 5-6, 5-7 or 5-8 gene product and wherein the plurality of TCRs do not consist essentially of TCRs comprising a TRAV12-2 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire and TCRs comprising a TRAV21 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire.Type: GrantFiled: September 15, 2016Date of Patent: October 5, 2021Assignee: Immunocore LimitedInventors: Peter Eamon Molloy, Arsen Valeryevich Volkov, Dhaval Jaykant Sangani, Graham Anthony Hood, Chandramouli Reddy Chillakuri
-
Patent number: 11124556Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.Type: GrantFiled: September 15, 2016Date of Patent: September 21, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
-
Patent number: 11017882Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: June 17, 2015Date of Patent: May 25, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 10980893Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: April 20, 2021Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
-
Patent number: 10946105Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: March 16, 2021Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
-
Patent number: 10937524Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.Type: GrantFiled: June 17, 2015Date of Patent: March 2, 2021Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
-
Patent number: 10851366Abstract: The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: December 1, 2020Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Maurits Kleijnen
-
Patent number: 10835577Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: November 17, 2020Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Chandramouli Chillakuri, Dhaval Sangani, Graham Hood, Alina Popa
-
Patent number: 10792333Abstract: The present invention relates to novel peptides derived from Actin-like protein 8 (ACTL8), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: October 6, 2020Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Alina Popa, Philip Addis
-
Patent number: 10576162Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.Type: GrantFiled: April 8, 2019Date of Patent: March 3, 2020Assignee: IMMUNOCORE LIMITEDInventors: Bent Karsten Jakobsen, Annelise Brigitte Vuidepot, Yi Li
-
Publication number: 20200040055Abstract: The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.Type: ApplicationFiled: June 2, 2017Publication date: February 6, 2020Applicant: Immunocore LimitedInventor: Christina COUGHLIN